Molina Healthcare (MOH) Stock Analysis & Forecast

Last earnings call, Jul 22, 2026 AI summary

What they said

Molina Healthcare reported Q2 2026 adjusted EPS of $1.51 on $10.2 billion of premium revenue with a consolidated MCR of 92.2% and a 1% adjusted pretax margin for the quarter (1.3% YTD). Medicaid performed in line with expectations (MCR 92.7%) and medical cost trend remained stable at the company’s 5% full-year assumption. Medicare performed materially better than expected (MCR 90.7%), driven by favorable duals performance and lower-than-expected trend, prompting management to increase Medicare guidance and to accelerate margin targets. Marketplace results were weaker (MCR 88.9%) due to prior-year risk adjustment and program-integrity items and an unfavorable current-year member acuity mix; management lowered marketplace expectations and now expects a $0.75 loss for the full year (including ~$1 of prior-year items). The company raised full-year adjusted EPS guidance by $0.25 to at least $5.25 while keeping premium revenue guidance unchanged at approximately $42 billion. Management highlighted strong capital metrics (parent cash to rise to ~$600M by year-end, debt-to-cap ~44%), operational discipline (G&A ratio ~6.5% this quarter, target below 6% with scale), AI upside for further G&A leverage, and one-time headwinds tied to the new Florida CMS contract (~$1.50 per share drag in 2026). Discussion in Q&A focused on exchange acuity and selection dynamics, Medicaid redetermination/work-requirements impacts, Medicare duals outperformance, Marketplace repricing/footprint reduction strategy, regulatory headwinds (IDR, state-directed payment limits, 1115 waivers), and the company’s confidence in achieving mid-term margin targets despite macro/regulatory risks.

Guidance

Full-year 2026 premium revenue unchanged at approximately $42.0 billion. Full-year 2026 adjusted EPS guidance increased by $0.25 to at least $5.25. Marketplace: full-year expected loss of $0.75 (includes ~$1.00 of prior-year items and ~$0.25 gain in current-year book). Medicare: segment guidance increased by $1.50 attributable to duals (company projecting duals trend ~4%). Parent company cash balance expected to be ~ $600 million by year-end; projected debt-to-cap ratio ~44% at year-end. Medical cost trend assumptions: Medicaid ~5% (full year), Medicare duals ~4%. Florida CMS contract expected to create a ~$1.50 EPS headwind in 2026 (with ~$0.50 G&A drag in Q3 pre-revenue, ~$0.50 one-time margin recognition in Q4, ~$0.50 higher MLR in initial quarter). 2027 commentary: preliminary outlook includes marketplace footprint reduction (potential ~$1B decline in exchange premium), and continued focus on profitable growth toward longer-term premium and EPS targets.

Risks flagged

Marketplace adverse selection and incomplete risk-adjustment capture (prior-year risk adjustment true-ups and program-integrity items). Regulatory and state-level funding headwinds including work requirements implementation uncertainty, 1115 waiver budget neutrality, caps on state-directed payments, provider tax changes, and potential reductions in federal funding that could pressure state rates. Industry arbitration/IDR process costs and program integrity exposure. Execution risk on Florida CMS onboarding and initial margins. Membership declines from repricing decisions and market exits. Timing/availability of dividends from state subsidiaries impacting parent cash (subsidiary-level variability).